ArticleEye (London, England)2026
Pachychoroid pigment epitheliopathy: long-term structural changes and risk factors for disease evolution.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pachychoroid diseases of the macula: an update.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePachychoroid pigment epitheliopathy (PPE) is an early, often asymptomatic stage of the pachychoroid disease spectrum that may progress to central serous chorioretinopathy (CSC), pachychoroid neovasculopathy, or polypoidal choroidal vasculopathy. This study evaluated longitudinal changes in retinal pigment epithelium (RPE) lesions in PPE and identified baseline predictors.
designRetrospective cohort study.
participantsForty-five eyes (45 patients) with PPE.
methodsAll patients underwent multimodal imaging, including near-infrared reflectance, optical coherence tomography (OCT), blue fundus autofluorescence, and OCT angiography. RPE alteration areas were quantified by projecting OCT B-scan delineations onto near-infrared images. Central subfield thickness (CST) and central choroidal thickness (CCT) were measured, along with choroidal thickness at four quadrants 500 µm and 1000 µm from the foveal centre.
main outcome measuresChange in total RPE lesion area at 1-year follow-up and baseline predictors of lesion progression.
resultsAt 1 year, total RPE lesion area increased significantly (median 0.81 mm² vs. 0.71 mm² at baseline; p < 0.001), with a median percentage increase of 10.5%. The number of discrete lesions remained unchanged. CST and CCT showed no significant longitudinal changes. Preliminary 2-year data (n = 13) demonstrated similar trends. Multivariable regression identified greater baseline CCT as independently associated with increased RPE lesion progression, whereas smaller baseline RPE areas were associated with a greater relative increase.
conclusionsPPE demonstrates progressive RPE alterations over time despite stable retinal and choroidal thickness. Greater baseline choroidal thickness and limited initial RPE involvement predict faster lesion expansion, supporting PPE as an active and evolving condition requiring regular multimodal monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.